newsfilter
← Latest News
Business Wire·

Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

– Apraglutide met the primary endpoint of relative change from baseline in actual weekly parenteral support (PS) volume at week 24, driven by both stoma and colon-in-continuity populations – – Apraglutide also showed